Covishield triggers more antibodies than Covaxin: Study

NEW DELHI: A latest study suggests Covishield triggers more antibodies than Covaxin; as part of this study, doctors and nurses received both doses of either of the two Covid-19 vaccines.

The study conducted by Dr AK Singh and his colleagues states that both vaccines elicited a good immune response. Unpublished data had earlier indicated that Covishield was found to be 70 per cent effective after the first dose. At the same time, preliminary data from its phase 3 trial put Covaxin's efficacy rate at 81 per cent.

So, while both elicited a good immune response after two doses, seropositivity rates and median anti-spike antibody titre was significantly higher in Covishield as compared to that in Covaxin.

Both vaccine recipients had similar solicited mild to moderate adverse events and none had severe or unsolicited side effects.